Accès gratuit
Numéro
Therapie
Volume 67, Numéro 4, Juillet-Août 2012
Page(s) 329 - 337
Section Recherche et développement / Research and Development
DOI https://doi.org/10.2515/therapie/2012046
Publié en ligne 1 novembre 2012
  1. Paintaud G, Tonelli D, Postaire E, et al. Biotherapies: are they just like any other drugs? Therapie 2007; 62: 235-39 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Paintaud G, Lejarre F, Ternant D, et al. Les anticorps monoclonaux : une avancée thérapeutique récente et majeure. Therapie 2009; 64: 1-7 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8 [CrossRef] [PubMed] [Google Scholar]
  4. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-57 [CrossRef] [PubMed] [Google Scholar]
  5. Congy-Jolivet N, Probst A, Watier H, et al. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit Rev Oncol Hematol 2007; 64: 226-33 [CrossRef] [PubMed] [Google Scholar]
  6. Lejeune J, Thibault G, Cartron G, et al. Rôle des récepteurs à la portion Fc des IgG (FcγRs) dans l’activité des anticorps thérapeutiques. Bull Cancer 2010; 97: 511-22 [PubMed] [Google Scholar]
  7. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-8 [CrossRef] [PubMed] [Google Scholar]
  8. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-96 [CrossRef] [PubMed] [Google Scholar]
  9. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcgRIIa-FcgRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-9 [CrossRef] [PubMed] [Google Scholar]
  10. Béliard R, Waegemans T, Notelet D, et al. A human anti-D monoclonal antibody selected for enhanced FcgRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008; 141: 109-19 [CrossRef] [PubMed] [Google Scholar]
  11. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgRIIIA/CD16. Br J Haematol 2008; 140: 635-43 [CrossRef] [PubMed] [Google Scholar]
  12. EMA. Guideline on development, production, characterization and specifications for monoclonal antibodies and related products. 2008 CHMP/BWP/157653/2007. http://www.ema.europa.eu [Google Scholar]
  13. EMA. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. 2007 EMEA/CHMP/BMWP/14327/2006. http://www.ema.europa.eu [Google Scholar]
  14. EMA. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. 2010 EMEA/CHMP/BMWP/86289/2010. http://www.ema.europa.eu [Google Scholar]
  15. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-28 [CrossRef] [PubMed] [Google Scholar]
  16. Afssaps. Essais cliniques de première administration à l’Homme, en dose unique d’un médicament expérimental (nouvelle substance active) : choix de la première dose, de la progression de dose et protocole d'administration aux volontaires. 2006. http://ansm.sante.fr/S-informer/Presse-Communiques-Points-presse/Premiere-administration-d-un-medicament-experimental-chez-l-homme-l-Afssaps-diffuse-des-recommandations-sur-les-essais-cliniques-de-phase-I/(language)/fre-FR [Google Scholar]
  17. EMA. Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products. 2007 CHMP/SWP/28367/2007. http://www.ema.europa.eu [Google Scholar]
  18. EMA. Guideline on similar biological medicinal products containing monoclonal antibodies. 2010 EMEA/CHMP/BMWP/403543/2010. http://www.ema.europa.eu [Google Scholar]
  19. Loisel S, Ohresser M, Pallardy M, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007; 62: 34-42 [CrossRef] [PubMed] [Google Scholar]
  20. Paintaud G. Pharmacocinétique des anticorps monoclonaux. Med Sci (Paris) 2009; 25: 1057-62 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  21. Magdelaine-Beuzelin C, Ohresser M, Watier H. FcRn, un récepteur d’IgG aux multiples facettes. Med Sci (Paris) 2009; 25: 1053-6 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  22. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005; 5: S37-S47 [CrossRef] [PubMed] [Google Scholar]
  23. Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 2009; 37: 25-47 [CrossRef] [PubMed] [Google Scholar]
  24. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9 [CrossRef] [PubMed] [Google Scholar]
  25. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011; 13: R105 [CrossRef] [PubMed] [Google Scholar]
  26. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358: 1109-17 [CrossRef] [PubMed] [Google Scholar]
  27. Zheng Y, Scheerens H, Davis JC Jr, et al. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther 2011; 89: 283-90 [CrossRef] [PubMed] [Google Scholar]
  28. Grudé F, Roué V, Beauchamp C, et al. Real cost linked to the introduction of targeted therapies (bevacizumab, cetuximab) and conventional chemotherapies in the treatment of metastatic colorectal cancer. Gastrointestinal Cancers Symposium, San Francisco 2009, A330 [Google Scholar]
  29. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-8 [CrossRef] [PubMed] [Google Scholar]
  30. Metges JP, Grudé F, Faroux R, et al. FOLFIRI bevacizumab in unresectable metastatic colorectal cancer in the true life, feasible in elderly patients: results of the cohort from OMIT Bretagne - Pays de Loire. Gastrointestinal Cancers Symposium, San Francisco, A398 [Google Scholar]
  31. Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology 2011; 50: 222-9 [CrossRef] [PubMed] [Google Scholar]